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Abstract: Epithelial-to-mesenchymal transition (EMT) is a key step in development, wound healing,
and cancer development. It involves cooperation of signaling pathways, such as transformation
growth factor-β (TGF-β), Sonic Hedgehog (SHH), and WNT pathways. These signaling pathways
crosstalk to each other and converge to key transcription factors (e.g., SNAIL1) to initialize and
maintain the process of EMT. The functional roles of multi-signaling pathway crosstalks in EMT
are sophisticated and, thus, remain to be explored. In this review, we focused on three major signal
transduction pathways that promote or regulate EMT in carcinoma. We discussed the network
structures, and provided a brief overview of the current therapy strategies and drug development
targeted to these three signal transduction pathways. Finally, we highlighted systems biology
approaches that can accelerate the process of deconstructing complex networks and drug discovery.
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1. Biomedical Significance of EMT
Epithelial cells are differentiated cells characterized by uniform cell shape, apical-basal polarity,
strong cell-cell adherent junctions, and cell-matrix hemidesmosomes, and limited mobility. Based on
these characteristics, epithelial cells normally form single-layered tubes or sheets to cover body, organs,
and compose glands [1,2]. On the contrary, mesenchymal cells have front-back polarity and loose cell
attachment. They typically have much higher mobility, which is closely related to their regeneration
function [3,4]. Mesenchymal cells reside in lymphatic, circulatory, and some connective tissues, and
give rise to some other types of cells in these tissues [5,6].
In 1968, Hay noticed that during chicken embryonic development, epithelial cells undergo
differentiation and dedifferentiation several times, as well as migrate a relatively long distance within
the body. All of these processes require inter-conversion between epithelial and mesenchymal
cell phenotypes, called epithelial-to-mesenchymal transition (EMT), and its reverse process,
mesenchymal-to-epithelial transition (MET) [7]. Subsequent studies showed that EMT and MET
are fundamental in amniotes’ gastrulation and neural crest formation, and generation of body patterns.
Specifically, during mammalian embryonic development, several rounds of EMT companied by
MET take place, which are generally assigned as primary, secondary, and tertiary EMT based on the
developmental stages [8]. The primary EMT occurs in early embryonic development, such as parietal
endoderm formation, mesoderm formation, and neural crest delamination. Signaling molecules that
initialize and regulate the primary EMT include the transforming growth factor-β (TGF-β) superfamily
(e.g., BMP, Nodal, etc.), the WNT family [9,10], and the fibroblast growth factor (FGF) family [11].
Two members in the SNAIL family, SNAIL1 and SNAIL2, are important during human early embryonic
development for repressing E-cadherin and weakening cell-cell junctions [12]. Mesodermal cells
generated from the primary EMT undergo MET subsequently and form secondary epithelial structures,
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such as the notochord and the somites. The transient epithelial structures go through the secondary
EMT and give rise to more differentiated structures, such as endocardial progenitors and connective
tissues. Some of the epithelial or mesenchymal structures from the secondary EMT-MET process
complete their final differentiation and maintain their phenotypes, provided there is no additional
inducing signals. Others continue on a tertiary EMT (and MET), again controlled by multiple signaling
pathways, and eventually give rise to complex organs, such as the lung [13] and heart [14].
In wound healing, the initial input signals are from injury. Transcription factors, such as ERK,
SLUG, and SNAIL [15–17], are activated to promote conversion of epithelial cells to a partial EMT
state. Partial EMT cells can be viewed as a hybrid of epithelial and mesenchymal cells. They also have
loose cell-to-cell connection, which allow them to migrate to wounding site. This process is reversible,
so the partial EMT cells turn back to the epithelial phenotype after the injury site has been healed and
the EMT triggering signal has been withdrawn [17].
Studies also support that EMT and MET take place during cancer metastasis. Some hypotheses
regard cancer as an overhealing wound [18] or an abnormal development process [19], while there
exist features specific for cancer progression. Invasion and metastasis are decisive steps in cancer
progression and the major cause for cancer-related mortality [20]. At the cellular level, EMT or partial
EMT leaves cells loosely connected to others, and enables them to depart from the primary location
and migrate along the circulatory system to a secondary location, where the migratory cells can go
through MET to epithelial cells again, proliferate, and form a secondary tumor [21]. Recent studies
suggest that partial EMT rather than full EMT may play key roles on cancer metastasis [22–24].
Though EMT in breast cancer was first observed in 1890s [25], it did not attract attention in
the carcinoma biology community for almost the whole past century. Only during the past decades
researchers discovered many crucial signaling pathways and core regulatory elements that induce
or contribute to EMT [8,26]. Like in embryonic development, metastasis in cancer progression can
also be induced by various signaling molecules or cytokines [27], such as proteins in the TGF-β
superfamily [28], hedgehog (HH) family, WNT family [29], and interleukin (IL) family [30], etc.
Stressful microenvironments, such as hypoxia [31] or free radicals [32], also trigger EMT [33].
2. Multiple Signal Transduction Pathway and Their Crosstalks
Figure 1 schematically summarizes the overall cellular process of sensing, relaying, and
responding to the stimulating signals. A plethora of stimuli activate multiple signal transduction
pathways, which then converge to a core regulatory network composed by transcription factors (such
as SNAIL1/2, ZEB1/2, TWIST) and miRNAs (such as miR34 and miR200 families) [34]. The latter
further interact with other regulatory elements to instruct a cell to choose one of the several possible
cell fates. For example, SNAIL1 can bind to P53, a major regulatory protein that induces senescence
or apoptosis, and trap free P53 in the cytosol. Thus, SNAIL1 inhibits the choice of senescence or
apoptosis [35]. Subsequently the fate decision is carried out by activating the corresponding expression
program, and is strengthened by a series of events such as epigenetic modifications and activation of a
number of feedback loops. The above flow-of-information is not unidirectional, but at every stage,
there exists negative and positive feedbacks to previous stages, and form a closed network.
The TGF-β, Sonic Hedgehog (SHH), and WNT pathways are three well-studied signal
transduction pathways that can induce EMT. Below we will give a general review on how these
three pathways participate in signal sensing and processing during EMT, and how the knowledge has
been applied to carcinoma treatment. Especially we hope to provide a perspective on the signaling
network based on systems biology approaches, and insights on biomedical interventions of EMT.
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Figure 1. Schematic of the overall signal reception, transduction, and response process of EMT.
Intracellular and extracellular signals are relayed via four basic units and regulated by positive and
negative feedback loops.
2.1. TGF-β Pathway
TGF-β i a type of secretive protein, and it affects the cell that secrets the protein (autocrine)
as well as its neighboring cells (paracrine). In human cells, three TGF-β isoforms (TGF-β1, TGF-β2
and TGF-β3) have been discovered, which share over 70% homological sequence. There are two
types of transmembrane TGF-β receptors (TGFBR). Generally, first the type II TGFBR (TGFBR-II)
molecules recognize and bind to TGF-β. Next, the complex recruits other TGFBRs and forms a complex
with a stoichiometry of two copies of TGFBR-I, two copies of TGFBR-II, and one copy of active
TGF-β. Formation of the complex activates the phosphorylation function of the intracellular part of
TGFBRs to relay the TGF-β sig als downstream of the pathway. The can nical pathway of TGF-β
involves phosphory ation and activation of SMADs. Meanwhile, TGFBR can also phosphorylate other
signaling proteins, such as kinases, or transmit the signals via crosstalking t other pathways [36].
Paradoxically, TGF-β functions as both carcinomatous repressor and activator. More specifically,
in normal cells or even some pre-cancer cells, TGF-β promotes proliferation arrest and, thus, represses
tumor growth. However, in advanced malignant carcinoma cells, TGF-β promotes EMT and tumor
metastasis. These seemingly contradictory functions come from the sophisticated regulation network
among two types of parallel TGF-β pathways [37,38].
2.1.1. SMAD-Dependent TGF-β Pathway
The more canonical TGF-β pathway epends on activation an eactivation of a SMAD family
(Figure 2a). In this pathway, signaling is cooperativel regulated by thre ypes of SMAD proteins
in this fa ily. Receptor-regulated SMADs (R-SMADs) include SMAD1, SMAD2, SMAD3, SMAD5,
and SMAD8. They receive signals transmitted from the membrane-embedded signal receptors, and
get phosphorylated [39]. Then, two molecules of phosphorylated R-SMADs come together and
recruit a common-mediator SMAD (co-SMAD), SMAD4, to form a trimer, which can be transported
from the cytosol into the nucleus [40–42]. In the nucleus, the heterotrimeric complex binds to
DNA-sequence-specific transcription factors, individually or with other co-activators, to activate
transcription of target genes [43], such as snail1 [44,45], snail2 [46,47], and other oncogenes. Inhibitory
SMADs (I-SMADs) have two members, SMAD6 and SMAD7. They are downstream targets of TGF-β
signaling, then negatively regulate activities of R-SMADs and co-SMADs [48], thus compose a negative
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feedback loop within the SMAD-dependent TGF-β pathway [49,50]. For instance, the active form
of SMAD6 competes with SMAD4 on target gene binding and thus prevents the targeted genes of
SMAD4 from being transcribed [51]. Similarly, the active form of SMAD7 interferes with activation of
TGF-β receptors and phosphorylation of R-SMADs [52].
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Elevated TGF-β-induced SMAD activation has been widely considered as a tumor promotion
event, especially in highly malignant cancer cells. On the other hand, many reports documented that
TGF-β-induced activation of SMADs also suppresses tumor formation and development by blocking
the cell cycle and arresting cell growth [53] in breast cancer cell lines [54], liver cancer cells [55], and
normal epithelial cells [56]. Mutations on smad2 and smad4 have been reported in colorectal cancer [57],
pancreatic ductal adenocarcinoma [58], or hepatocellular cancer [59]. These mutations implicate the
potential antitumor function of SMADs [60,61]. Moreover, depending on cell types, TGF-β induced
SMAD signals can also induce apoptosis as a safeguard mechanism to prevent transformed cell from
EMT or metastasis [62,63].
The diverse roles of SMAD activation come from how the SMAD2/3/4 heterotrimeric complex
performs its function. When the SMAD trimer acts alone, some of the targeted genes can be activated
only at a low basal level. More efficient activation of these genes requires binding of the trimer to
other sequencing-specific activators [64]. For example, the SMAD2/3/4 complex recruits CBP/P300 as
the co-activator to activate p15 [65] and p21 [66], both of which inhibit cells from progression of cell
cycles [67]. On the other hand, if the heterotrimer recruits EMT promoting transcription factors as the
co-activator, such as TWISTs, it can up-regulate oncogene expression [68]. This cofactor-dependent
gene expression pattern explains why TGF-β functions differently in cells of different type and cell
stage, and the outcome is affected by the existence of other stimuli.
2.1.2. SMAD Independent Pathway
Other than the SMAD-dependent pathway, TGF-β receptors also relay the signals through a
group of additional signal-transmitting proteins, such as PI3K/AKT, MEK/ERK1/2 [69], RHO-A, and
JNK/P38 [70]. Compared to the SMAD-dependent pathway, the SMAD-independent pathways
are even more complicated, with crosstalks among the signaling proteins forming an intricate
molecule-molecule interaction network. For instance, TGF-β can induce AKT phosphorylation and
activate phosphatidylinositol 3-kinase (PI3K) rapidly, which possibly contributes to SMAD2-induced
EMT [71]. Studies on keratinocyte cells show that the PI3K/AKT pathway helps to complete the
TGF-β-induced SMAD-dependent EMT [72]. Furthermore, PI3K and AKT antagonize TGF-β-induced
apoptosis and growth arrest [73,74], and bias TGF-β-treated cells to undergo EMT. Similarly, the
TGF-β-induced ERK/MAPK pathway contributes to EMT induction, since ERK is required for
removing cell adherens junctions to increase cell mobility. TGF-β also activates RHO-like GTPases
in the RHO pathway, which have multiple functions on cytoskeletal organization, apoptosis,
and EMT [75], as well as the RHO-A-dependent signaling pathway to promote mesenchymal
characteristics in epithelial cells through inducing stress fiber formation [70,76]. Another TGF-β
induced SMAD-independent pathway is the JNK/P38 pathway via the activation of TGF-β activated
kinase 1 (TAK1). JNK itself can phosphorylate R-SMAD directly, thus, turning on the EMT program.
Both JNK and P38 can work synergistically with SMADs to promote TGF-β induced apoptosis [70,77].
Put all of the above together, at pro-oncogenic stage, TGF-β has opposing effects on tumor
development. Some of the SMAD-independent pathways have tumor-suppressing functions, such as
promoting apoptosis. However, the SMAD-independent pathways can also promote tumor development
through suppressing apoptosis and promoting EMT [70]. Physiologically, at the pre-tumor stage the
SMAD-dependent pathway promotes cell cycle arrest and apoptosis to stop tumor formation and growth.
In malignant cells, when the amount of cofactors of oncogenes exceeds that for apoptosis or growth arrest,
TGF-β functions more as an EMT-inducer through both SMAD-dependent and SMAD-independent
pathways. Therefore, in cancer progression, the relative balance between SMAD-dependent and
-independent signal transduction likely plays a critical role on determining cell fates [70].
2.1.3. Drugs Targeted to TGF-β Pathway
Based on its cancer-promotion function, members of the TGF-β family are potential drug
targets for clinic therapy. Moreover, given the fact that the TGF-β pathway involves in DNA
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damage repair [78], inhibition of TGF-β signaling may enhance the efficacy of radiotherapy and
chemotherapy [79]. Popular clinical treatments that target to blocking TGF-β signaling include
trapping TGF-β ligands, blocking the receptor kinases signaling, using antisense oligunucleotides
to decrease the translation of TGF-β protein, and using peptide aptamers to block the transduction
pathway [80]. For example, to trap TGF-β molecules from binding to TGFBRs, 1D11 [81], and GC-1008
(Fresolimumab) [82] have been generated as TGF-β neutralization monoclonal antibodies and used
in treatment of melanoma [83] and glioblastoma [84]. AP12009 (Trabedersen) is designed to inhibit
TGF-β2 expression and has been used to treat pancreatic cancer [85]. Small chemical molecules are
developed to block TGF-β signaling by inhibiting the phosphorylation function of TGFBRs, among
them SB431542 is widely used to inhibit TGFBR-I in breast cancer therapy [86,87] and LY2109761 is
another TGFBRs inhibitor that is applied in treating pancreatic cancer [88]. Antibodies raised against
targeted proteins in TGF-β pathways can also be used as therapeutic approach. For example, the
primary tumor growth are proven to be arrested by TGFBR-II antibodies [89]. Development of peptide
aptamer drugs is a new direction that is still at its early stage. Some peptide aptamers targeting
R-SMADs or co-SMAD have been discovered and tested in cell lines [90]. Since they target specific
proteins, using peptide aptamers might be a more promising clinical therapy strategy considering
the dual roles of TGF-β. By blocking only one sub-TGF-β-pathway, one can possibly suppress the
tumor-promotion function of TGF-β without removing its anti-tumor benefits.
Therapeutic blockage of TGF-β signaling is tricky due to the pleiotropic effects of TGF-β on tumor
progress. As a secretive protein, controlling the TGF-β signaling microenvironment near carcinoma
is as important as controlling the intracellular TGF-β signaling pathway. Moreover, TGF-β has
important regulatory functions on normal cell physiology. Complete blockage of the TGF-β pathway is
detrimental to normal cells and thus not recommended. Therefore, while significant progress has been
made on developing drugs that target the TGF-β signaling pathways, clinically, these drugs should be
used with caution and perhaps only in certain cancer types.
2.2. SHH Pathway Engages in EMT and Crosstalks to TGF-β
In addition to the TGF-β pathway, the SHH pathway has been reported to induce EMT
individually, or cooperated with other pathways in lymphatic and gastric tumors [91], pancreatic
cancer [92], breast cancer [93], etc. (Figure 2b).
Like the TGF-β pathway, the SHH pathway starts from secretive hedgehog proteins, a family of
glycoproteins. The precursors of SHH proteins undergo several steps of post-translational modification
and cleavage before maturation, which are then secreted as oligomers or soluble multimers, and can
diffuse over various distances between tissues in the body before being removed [94]. SHH belongs
to the hedgehog (HH) family. Three mammalian HH proteins have been identified in the HH family
recently, sonic hedgehog (SHH), Indian hedgehog (IHH) and desert hedgehog (DHH). While these
three HH proteins share some redundant functions, each of them also has evolutionarily-specified
roles. For example, Sonic Hedgehog (SHH), the most common and understood one, is crucial in
embryo development, cancer progression, and body patterning [95,96].
2.2.1. The off and on States of the SHH Pathway
The canonical SHH pathway can be generally divided into three parts; the signal reception
elements, the signal transmission elements, and downstream transcription factors. In the absence of
SHH, the pathway is at an “off” state. HH-patched protein (PTC), which is the transmembrane receptor
element, binds to smoothened protein (SMO) to inhibit SMO activation. In the cytosol, activated protein
kinase A (PKA) binds to other kinases including glycogen synthase kinase 3β (GSK3β) and other
factors to phosphorate glioma-associated oncogene homologs (GLIs). In the absence of SHH signals,
GLIs have only low basal level expression, and the proteins assume a repressor form. That is, GLIs
repress the expression of their target genes. When SHH is present, the pathway switches to an “on”
state. SMO proteins are released and phosphorylated to promote the activation of GLIs [97–99].
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Some GLI proteins (e.g., GLI2) are truncated at the carboxy-terminal by the proteasome and turn to the
activator form [100,101], which then activate the expression of their target genes.
2.2.2. Regulation of GLI Proteins and Crosstalk to the TGF-β Pathway
GLI proteins are the major transcription factors in the SHH pathway. A high level of GLI proteins
indicates activation of the SHH pathway [102]. Three types of GLI proteins have been identified in
mammals, GLI1, GLI2, and GLI3. Though they share long homologue sequences, and also have similar
DNA-binding sequences, they play quite different roles in development, EMT, and cancer promotion.
In addition to the DNA binding domain, GLI1 has only the activator domain and can be activated by
SHH. GLI2, and GLI3 have both the repressor domain and the activator domain. However, in most
contexts, SHH activates GLI2 [103], while it is unclear SHH activates or represses GLI3 [104].
Activated GLI1 and GLI2 can directly promote the expression of a group of genes by physically
binding to their promoter region, including oncogenes and genes that are involved in the EMT
process [105], such as bmi1 [106], nanog [107], snail1 [108,109]. Based on the fact that expression of
GLI1 can be regulated by the E-box [110], positive feedback loops may exist between GLI1 and its
target transcription factors that contain E-box at the promoter region of their genes, such as SNAIL1.
Furthermore, GLI proteins can also be up-regulated by SMAD proteins [111,112]. Actually, the
TGF-β/SMAD/GLI2 axis has been suggested to be essential for cancer metastasis [113]. Consequently,
the SHH pathway and the TGF-β pathway crosstalk to each other and coordinately induce EMT. GLI
proteins are also involved in several positive or negative feedback loops within the SHH signaling
pathway. For example, the activated form of GLI2 can directly bind to the promoter region of gli1 to
up-regulate GLI1 protein expression, while GLI1 can also induce GLI2 expression directly or indirectly,
so the two form a positive feedback loop [103,114]. On the other hand, GLI1 induces PTC, and PTC
inhibits GLIs to form a negative feedback loop [103].
2.2.3. Clinical Observation and Interventions of SHH Signaling Pathway in Cancer
There are clinical reports on abnormal activation of the SHH signaling pathway in different
types of cancer. For example, in thyroid cancer, SHH is expressed in 64% of PTC tissues but only
in 17% of non-cancerous tissues, and GLI1 is expressed in 48% and 9% of these two different types
of tissues, respectively [115]. Activation of the SHH pathway is related to promotion of the EMT
process in lung cancer cell lines [116], renal cell cancer [117], and gastric cancer [91]. Based on these
observations, blocking SHH signaling is a popular strategy in cancer therapy. Indeed, inhibition of
SHH signaling can reduce the proliferation rate of non-small-cell-lung-cancer cells significantly [118].
A similar phenomenon has also been observed in breast cancer [119].
A basic strategy of intervening the SHH pathway is blocking the SHH receptor or other
major players downstream in this pathway [104]. In pancreatic cancer therapy, combination of a
SMO inhibitor, cyclopamine, and gemcitabine, a nucleotide analog, completely abrogate pancreatic
cancer metastasis while also significantly reduce the size of the primary tumor [120]. Cyclopamine,
vismodegib, and other SMO inhibitors have been used widely in clinic for medulloblastoma [121],
ovarian cancer [122], and pancreatic cancer [123] treatment. Given the importance of GLI1/2 in
the SHH pathway on promoting EMT and metastasis, blockade of GLI1/2 is a candidate for cancer
treatment. For example, small chemical molecules, GANT58 and/or GANT61, which block GLI1/2
function, arrest prostate tumor growth [124]. Compared to blocking the upstream regulators in the
SHH pathway, an advantage of targeting GLI proteins is that these proteins serve as signaling hubs of
multiple pathways that are activated in cancer cells, such as the TGF-β, WNT, and SHH pathways.
2.3. WNT Pathway in Cancer Progress and EMT
The WNT pathway is another signaling pathway that crosstalks to the TGF-β pathway and
promotes EMT. The tumor repressor GSK3β, and the activator β-CATENIN are two major converging
elements between the WNT and TGF-β pathways (Figure 2c).
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The WNTs comprise a large family of proteins that are highly conserved from fruit fly to
human [125]. In homo species, 19 discovered WNTs compose a very intricate network, which is essential
for development and stress responses. Abnormal activation or mutations in the WNT pathway has been
reported in many cancer types, such as intestinal neoplasms, breast cancer, prostate cancer, and lung
cancer [126].
The canonical WNT pathway starts from reception of signaling molecules on the cell membrane.
GSK3β is a major downstream regulator of the receptors. Without WNT signals, GSK3β keeps its active
form, which can phosphorylate its target proteins (e.g., β-CATENIN [127]) for further degradation.
When the WNT signaling pathway is activated, GSK3β is phosphorylated to an inactive form. Thus,
functional β-CATENIN is accumulated in the cytosol and is further transported into the nucleus. In the
nucleus, together with TCF/LEF, β-CATENIN binds to the promoter region of a target gene, such as
SNAIL1, and activates its transcription [9,128]. Furthermore, SNAIL1 can also form a positive feedback
with β-CATENIN by interacting with the β-CATENIN physically [129], or increase the amount of free
β-CATENIN indirectly through EMT process [130]. Inactivation of GSK3β can also increase SNAIL1
expression directly following two steps: in the nucleus, it is phosphorylated by GSK3β; then SNAIL1
can be transported from the nucleus to the cytosol, where it can be phosphorylated again by GSK3β
for final degradation [131].
The WNT pathway affects and is affected by several signaling pathways, including the SHH and
TGF-β pathways. GSK3β affects GLI proteins both positively and negatively. On one hand, GSK3β
phosphorylates GLI proteins for degradation [132]. On the other hand, GSK3β phosphorylates SUFU,
a scarf protein for GLI proteins, and releases free GLI proteins [133]. GSK3β also stabilizes GLI mRNA
indirectly, leading to an increase of the amount of GLI proteins [134]. Subject to TGF-β stimulation,
the WNT pathway can be activated by SMAD-independent pathways. For instance, in human lung
fibroblast cells, TGF-β1 can inactivate GSK3β by activating the mitogen-activated protein kinase
(MAPK) pathway and phosphorylating ERKs [135]. GSK3β can be inhibited by the ARK pathway,
and the latter can be activated by TGF-β1 in some cell lines. In addition, GSK3β negatively affects the
TGF-β pathway by phosphorylating SMAD3 with its cooperator, AXIN, and triggers its ubiquitination
and degradation when TGF-β is absent [136].
Clinical Observation and Interventions of the WNT Signaling Pathway in Cancer
Based on the well-documented close relationship between WNT signaling aberrance and cancer,
intensive efforts have been put on designing drugs that specifically target the WNT pathway [137].
However, no drug has been approved for clinical usage yet [138]. Special caution has to be taken
since the WNT pathway has important functions in almost every aspect of mammalian cells, such as
proliferation and regeneration.
In addition to target-specific small molecules, a group of drugs and compounds widely used for
other purposes have been proven to help in cancer treatment as they also block the WNT pathway.
For example, aspirin affects and blocks the WNT pathway as a non-steroidal anti-inflammatory
drug (NSAID) at multiple levels, such as facilitating β-CATENIN degradation [139]. Vitamins, such
as retinoids, vitamin D, etc., show effects in colorectal cancer and breast cancer probably through
interacting with β-CATENIN and TCFs [137].
3. Systems Biology in Signaling Crosstalk and Drug Discovery
As we discussed above, the crosstalk network among the TGF-β, SHH, and WNT signaling
pathways is complex. In addition, some of the signals, such as TGF-β, have opposite roles as both
cancer repressor and promoter, depending on cell types and cancer stages. Similarly, some of the
regulators can both turn “off” and “on” their target genes. For example, GLI proteins can both
negatively and positively regulate expression of themselves. Another typical example is GSK3β,
which can covalently modify both oncogene proteins (e.g., SNAIL1) and tumor repressors (SUFU) for
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degradation [133]. Furthermore, all of these signaling pathways have essential roles on both normal
cell life cycle and in cancer development.
Due to the above-mentioned molecular biology complexity, a naive drug-design strategy based
on simply blocking certain pathway likely has serious side effect to normal cells and patients.
Cancer therapy and anti-tumor drug discovery are, thus, difficult, time consuming, and face three
basic challenges:
1. Which of the proteins/regulators to target for clinic and commercial consideration?
2. How to select chemicals that are suitable for therapy from the gigantic data pool?
3. How to design treatments that target to specific population of tumors in patients?
Currently computational and system biology studies become indispensable on revealing the
molecular mechanism and addressing the three challenges. These studies engage widely in current
molecular biology, and provide systematic and integrative perspectives on understanding the biological
implications underlying individual experimental results. In the next section we will use a series of
recent studies to illustrate how we can advance our understanding of the EMT regulatory mechanism
through combined mathematical modeling and experimental studies.
With increasing reports on new signals and pathways leading to EMT, one might have the
impression that EMT can be induced easily. Actually, EMT is tightly regulated at multiple levels, and
pathological EMT is a rare event in a healthy body. Furthermore, EMT is not a “to be or not to be”
question. Instead, EMT proceeds through a wide spectrum of intermediate states, generally referred
as the partial EMT state [140,141]. Tian et al. [142] mathematically analyzed the core EMT regulatory
network (Figure 3a), and proposed a sequential two-step mechanism, as summarized in Figure 3b.
A SNAIL1/miR34 double negative feedback loop and a ZEB1/miR200 feedback loop form two binary
switches. In epithelial cells, both miR34 and miR200 are highly expressed, while SNAIL1 and ZEB1
express only at basal levels. With an intermediate concentration of TGF-β (exceeding a threshold
value Ca), snail1 transcription is activated. The protein product SNAIL1 further inhibits transcription
of miR34 [143], partially up-regulates epithelial markers such as E-cadherin and down-regulate
mesenchymal makers such as Vimenten and N-cadherin. At this stage, the ZEB1/miR200 switch has not
been reverted, and cells exist in a partial EMT state. Experimentally, if one now reduces the exogenous
TGF-β to a lower level (below a threshold value Ca’ < Ca), cells returns to the epithelial state. That is, the
Epithelial-to-partial EMT transition is reversible under TGF-β treatment. When the exogenous TGF-β
level exceeds a second threshold (Cb > Ca), miR200 is degraded and the level of ZEB1/2 increases.
ZEB further inhibits transcription of miR200 [141], works together with SNAIL1 and other factors to
up-regulate epithelial markers and down-regulate mesenchymal makers, so cells undergo a full EMT.
At this stage cells express autocrine TGF-β, which maintains cells in the mesenchymal state even when
the exogenous TGF-β is removed (the crucial point Cb’ < 0). That is, the full EMT is irreversible under
TGF-β treatment. Subsequently, Zhang et al. [144] performed quantitative experimental studies using
the human mammary MCF10A cell line, and confirmed all model predictions. Therefore, the studies
reveal how different cell phenotypes emerge out of the interactions among the transcription factors and
microRNAs, and provide clues for biomedical intervention to regulate the conversion between them.
The above-mentioned model clearly does not provide a complete picture on EMT but rather
should be considered as a starting point. It only considers a small core network without explicitly
considering many other key EMT players such as TWIST. Actually there are many more positive
feedback loops formed by various regulating elements. These feedback loops can also form multiple
stable switches [145], which may function either in synergy or in sequence to give rise to possibly
a combinatorial number of partial EMT states, consistent with the notion of a quasi-continuum
EMT spectrum [146]. Further experimental studies can also analyze whether the revealed two-step
mechanism is general for different cell types and cell lines, and if not (which is very likely), what
are the differences and common themes. While there are many possible directions for expanding the
modeling efforts, below we discuss three of them.
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First, the model can be systematically expanded to include other involved molecular species.
Using a more coarse-grained Boolean network modeling framework, recently Steinway et al. studied a
more complex network of EMT including crosstalks among the TGF-β, SHH, and WNT pathways,
and tested model predictions experimentally [147,148]. Expansion of an ordinary differential equation
based model like ours can more faithfully describe the temporal and steady state dynamics of the
system. For this purpose systematic and quantitative measurements are needed to provide input for
constraining model parameters and testing model predictions.
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Figure 3. Systems biology study on the core EMT network. (a) Core regulatory network of TGF-β induced
EMT revealed by experimental studies. Point arrows represent activation, and blunt ones represent
inhibition; and (b) mathematically-predicted bifurcation diagram. Also shown are the corresponding
dose-response (D-R) curves that are more familiar to experimentalists. Notice that the D-R curves
are different for cells starting from different phenotypes and treated with increasing (blue curve) and
decreasing (purple curves) exogenous TGF-β, respectively. This history-dependent hysteresis is a
signature of bistable dyna ics. The predicted bifurcation diagram has been experimentally confirmed in
MCF10A cells. Adapted from [142,144].
Second, the field awaits further methodology developments on incorporating high-throughput
data into detailed dynamics modeling. The past decade has observed an explosion of accumulation
of “omics” datasets, such as transcriptomics, epigenomics, proteomics, and metabolomics. Typically
a high-throughput dataset provides a global view of a system or process under study, although at
relatively low resolution, both in temporal features and in dat quality, compared to a more focused
study like the es discussed above. Bioinformatics tools have been widely used to nalyze the omics
data. For example, Nam, et al. used PATHOME, an algorithm based on ntire p thway information,
to connect the WNT and AMPK pathways at HNF4a-WNT5A in gastric carcinogenesis, and further
predict WNT5A as a suitable therapy target [149]. Given the importance of including dynamics into
pharmaceutical development [150,151], the challenge is how to combine these global and focused
levels of studies.
Third, we may observe more examples of integrating computational and systems biology
approaches in new drug discovery, especially in screening the druggable structure of targeted
proteins a d selecting drug candidat s [152]. Computational structure biology has already been
used widely in drug a didate screening. For example, Baken et al. analyzed a pharmacophore model
(PM), and selected seven compounds for further experimental screening out of over two million
candidates [153]. The procedure can be more efficient and effective by placing drug discovery in the
context of network dynamics.
In summary, EMT is a complex process and many pathways crosstalk extensively to initialize and
regulate EMT. Therefore, integrated computational and experimental approaches are necessary to tackle
the molecular and cellular regulation mechanisms, and optimize biomedical intervention strategies.
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